Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Veregen for primary superficial basal cell carcinoma
2013-005439-26Phase 2Completed
- Sponsor
- Maastricht University Medical Center+
- Start
- Jan 2014
- Modality
- Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in basal cell carcinoma (BCC) comparing Veregen arm with Placebo arm (2 arms). Primary endpoint: Histological clearance of the target tumor. Started Jan 2014; status: completed.
02
Drugs
sinecatechins
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on 2013-005439-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005439-26.